The Ovarian Assessment Report (OAR) from ReproSource® provides the most reliable assessment of egg supply via a convenient blood test.1 This comprehensive test panel looks at levels of multiple ovary-related hormones combined with the patient’s age to calculate her personal Egg Supply Score (ESSTM). The Egg Supply Score is an easy-to-understand number that correlates more closely to egg supply than stand-alone hormone testing.2,3

  • Accurate: The OAR test is the most reliable blood test to estimate egg supply. Results are calibrated to clinical outcome.1-3,7
  • Patient Friendly: The Egg Supply Score allows ease of counseling and can aid patients in planning their reproductive future.

The Egg Supply Score (ESS)

In a clinical study of 454 egg-retrieval procedures, the ESS was calibrated directly to egg supply and demonstrated higher accuracy in predicting eggs retrieved than individual hormone levels such as AMH and FSH.2,3 The OAR test is used by leading academic and private fertility specialists.

The American College of Obstetricians and Gynecologists (ACOG)
recommends offering ovarian reserve testing (e.g. AMH, FSH, and Estradiol)
to women at risk of diminished ovarian reserve and to women older than
35 years who have not conceived after six months of attempting pregnancy.4

Benefits of the OAR test

Chart: benefits of OAR test

Test Limitations

Use of hormonal contraceptives within 8 weeks prior to testing may alter hormone levels assessed by the test. Conditions such as ovarian cysts may also alter hormone levels. Sample should be drawn on day 2– 4 of patient’s reported menstrual cycle (day 1 is the first day of full menstrual flow). Submitting samples outside of recommended guidelines may produce less accurate results.

Indications for Testing

  • Age >35 years and desiring pregnancy
  • Ovarian surgery (e.g. removal of cyst or endometrioma)
  • Conditions damaging to ovaries (e.g. endometriosis, pelvic inflammation)
  • Exposures toxic to ovaries (e.g. chemotherapy, pelvic irradiation)
  • Family history of early menopause
  • Smoking
  • Genetic factors (e.g. Turner syndrome mosaic, Fragile X carrier)
References (**ReproSource Publications)
** 1. Riggs RM et al. Assessment of ovarian reserve with anti-Müllerian hormone: a comparison of the predictive value of anti-Müllerian hormone, follicle-stimulating hormone, inhibin B, and age. Am Jrn of Obst and Gynec 2008 Aug;199(2):202 e1-8.
** 2. Leader B et al., Index predicts number of oocytes at retrieval in fertile and infertile women. Hum Reprod 2008;23(Sup1);i80
** 3. Leader B et al., Index outperforms AMH, inhibin B, and FSH in predicting poor egg supply. Fert and Ster 2008;90(1);S263-S264.
4. Ovarian reserve testing: a committee opinion. Practice Committee of the American College of Obstetricians and Gynecologists on Gynecologic Practice 2015 No. 618.
** 5. Leader B, Baker VL. Maximizing clinical utility of antimüllerian hormone (AMH) testing in women’s health. Current Opinions in Obstetrics and Gynecology 2014 Aug;4.
6. Iliodromiti S, et al., Can anti-Müllerian hormone predict the diagnosis of polycystic ovary syndrome? A systematic review and meta-analysis of extracted data. Jrn Clin Endoc and Metab 2013;98(8):3332-3340.
** 7. Tal R, et al., Characterization of women with elevated antimülerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes. Amer Jrn Obstet Gynec Epub 2014 Mar 2.
ReproSource®, OAR™ and ESS™ are trademarks or registered trademarks of ReproSource, Inc.